lexiara

1.

The sponsor of an orphan medicinal product may, prior to the submission of an application for marketing authorisation. request advice from the Agency on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product, in accordance with Article 51(j) of Regulation (EEC) No 2309/93.

· All articles ·

Source: EUR-Lex (Cellar) · retrieved 2026-11-21 · Text as adopted (Official Journal); later amendments are not incorporated in this text.